This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Micolette

OTC
Read time: 1 mins
Last updated: 06 Apr 2018
...
 

Summary of product characteristics


1. Name of the medicinal product

Micolette Micro-enema


2. Qualitative and quantitative composition

Sodium lauryl sulphoacetate

45 mg )

Sodium citrate BP

450 mg ) per 5 ml

Glycerol BP

625 mg )


3. Pharmaceutical form

Micro-enema


4.1. Therapeutic indications

Micolette is indicated whenever an enema is necessary for chronic and acute constipation in the rectum and sigmoid colon. Also indicated for use in constipation in geriatrics, pediatrics and obstetrics.


4.2. Posology and method of administration

Route of administration: Rectal

Adults and children aged 3 years and over:

Lubricate the nozzle with one drop of the contents; insert full length of nozzle into the rectum and squeeze tube until total contents have been administered. Two tubes may be necessary in severe cases. When used in children the nozzle should be inserted to half its length only.Children under 3 years: Not recommended.Elderly: There are no special requirements for elderly patients but as with all medicines the lowest effective dose should be used.


4.3. Contraindications

Inflammatory or ulcerative bowel disease. Acute gastrointestinal conditions.


4.4. Special warnings and precautions for use

Excessive use of Micolette micro-enema may cause diarrhoea and fluid loss. In such cases, Micolette should be discontinued and appropriate therapy instituted.


4.5. Interaction with other medicinal products and other forms of interaction

Prolonged use may interfere with the absorption of some vitamins.


4.6. Fertility, pregnancy and lactation

Indicated for use in constipation in obstetrics.


4.7. Effects on ability to drive and use machines

Not applicable.


4.8. Undesirable effects

Very occasionally, a slight cramp may occur. Prolonged use may lead to irritation of the anal canal.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.


4.9. Overdose

Not applicable.


5.1. Pharmacodynamic properties

Sodium citrate is a 'peptizing' agent which liberates water present in the faeces. Sorbitol enhances this action. Sodium lauryl sulphoacetate is a wetting agent. Glycerol promotes peristalsis and evacuation of the lower bowel.


5.2. Pharmacokinetic properties

Not applicable.


5.3. Preclinical safety data

Not applicable.


6.1. List of excipients

Sorbitol solution BP

3.12 g

Potassium sorbate BP

6.2 mg

Water

6.25 g


6.2. Incompatibilities

None known


6.3. Shelf life

60 months (unopened).


6.4. Special precautions for storage

Store below 25°C


6.5. Nature and contents of container

Disposable low density polyethylene tube with nozzle and removable cap.(Pack of 12 x 5 ml tubes).


6.6. Special precautions for disposal and other handling

Not applicable.


7. Marketing authorisation holder

Pinewood Laboratories LimitedBallymacarbry,Clonmel,Co. TipperaryIreland.


8. Marketing authorisation number(s)

PL 04917/0064


9. Date of first authorisation/renewal of the authorisation

15 August 2003/ 09 March 2009


10. Date of revision of the text

24/06/2015

4.1 Therapeutic indications

Micolette is indicated whenever an enema is necessary for chronic and acute constipation in the rectum and sigmoid colon. Also indicated for use in constipation in geriatrics, pediatrics and obstetrics.

4.2 Posology and method of administration

Route of administration: Rectal

Adults and children aged 3 years and over:

Lubricate the nozzle with one drop of the contents; insert full length of nozzle into the rectum and squeeze tube until total contents have been administered. Two tubes may be necessary in severe cases. When used in children the nozzle should be inserted to half its length only.Children under 3 years: Not recommended.Elderly: There are no special requirements for elderly patients but as with all medicines the lowest effective dose should be used.

4.3 Contraindications

Inflammatory or ulcerative bowel disease. Acute gastrointestinal conditions.

4.4 Special warnings and precautions for use

Excessive use of Micolette micro-enema may cause diarrhoea and fluid loss. In such cases, Micolette should be discontinued and appropriate therapy instituted.

4.5 Interaction with other medicinal products and other forms of interaction

Prolonged use may interfere with the absorption of some vitamins.

4.6 Fertility, pregnancy and lactation

Indicated for use in constipation in obstetrics.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

Very occasionally, a slight cramp may occur. Prolonged use may lead to irritation of the anal canal.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Drug section

Journals
Journal
Bezlotoxumab for the prevention of Clostridium difficile recurrence.

Introduction:Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of recurrence. Currently recommended treatments are not efficient for prevention...

1 mins
Journal
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Background: Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients. Recurrences are common after antibiotic therapy.

1 min
Journal
Faecal microbiota transplantation: a regulatory hurdle?

During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation.

1 min
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).